MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs

Summary

Immunomodulatory drugs (IMiDs) are associated with an increased risk of venous thromboembolism (VTE) in multiple myeloma (MM) patients. We designed MELISSE, a multicentre prospective observational study, to evaluate VTE incidence and identify risk factors in IMiDstreated MM. Our objective was to determine the real-life practice of VTE prophylaxis strategy. A total of 524 MM patients were included, and we planned to collect information at baseline, at four and at 12 months, on MM therapy, on VTE risk factors and management. VTE incidence was 7% (n=31), including 2.5% pulmonary embolism (PE) (n=11), similar at four or 12 months. VTE was observed at all risk assessment levels, although the increased risk assessment level correlated to a lower rate of VTE, maybe due to the implemented thromboprophylaxis strategy. VTE occurred in 7% on aspirin vs 3% on lowmolecular- weight heparin (LMWH) prophylaxis, and none on vitamin K antagonists (VKA). New risk factors for VTE in IMiDs-treated MM were identified. In conclusion, VTE prophylaxis is compulsory in IMiDstreated MM, based on individualised VTE risk assessment. Anticoagulation prophylaxis with LMWH should clearly be prioritised in MM patients with high VTE risk, along with VKA. Further prospective studies will identify most relevant VTE risk factors in IMiDs-treated MM to select accurately which MM patients should receive LMWH prophylaxis and for which duration to optimise VTE risk reduction.

Keywords

Myeloma - deep venous thrombosis - risk factors - immunomodulatory drugs

• References

• 1 Menon SP, Rajkumar SV, Lacy M. et al. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008; 112: 1522-1528.
• 2 Zamagni E, Brioli A, Tacchetti P. et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011; 37: 209-219.
• 3 Coppola A, Tufano A, Di Capua M. et al. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 2011; 37: 929-945.
• 4 Carrier M, Le Gal G, Tay J. et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9: 653-663.
• 5 Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 2009; 123: 679-686.
• 6 Leebeek FW, Kruip MJ, Sonneveld P. Risk and management of thrombosis in multiple myeloma. Thromb Res 2012; 129 (Suppl. 01) S88-S92.
• 7 Palumbo A, Rajkumar SV, Dimopoulos MA. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
• 8 Mateos M. Management of teatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010; 36: S24-S32.
• 9 Palumbo A, Davies F, Kropff M. et al. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Ann Hematol 2010; 89: 803-811.
• 10 Snowden JA, Ahmedzai SH, Ashcroft J. et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011; 154: 76-103.
• 11 Hovens MM, Snoep JD, Tamsma JT. et al. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006; 4: 1470-1475.
• 12 Niesvizky R, Martinez-Banos D, Jalbrzikowski J. et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007; 48: 2330-2337.
• 13 Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
• 14 Carrier M, Khorana AA, Zwicker JI. et al. subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost 2012; 10: 2599-2601.
• 15 Anaissie EJ, Coleman EA, Goodwin JA. et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer 2012; 118: 549-557.
• 16 Larocca A, Cavallo F, Bringhen S. et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119: 933-939.
• 17 Palumbo A, Cavo M, Bringhen S. et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29: 986-993.
• 18 Cohen AT, Skinner JA, Kakkar VV. Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?. Br Med J 1994; 309: 1213-1215.
• 19 Palumbo A, Rus C, Zeldis JB. et al. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006; 4: 1842-1845.
• 20 N.N. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-1302.
• 21 Zangari M, Barlogie B, Anaissie E. et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715-721.
• 22 Chen C, Reece DE, Siegel D. et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146: 164-170.
• 23 Rajkumar SV, Jacobus S, Callander NS. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
• 24 Fuste B, Serradell M, Escolar G. et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678-685.
• 25 Tobu M, Iqbal O, Fareed D. et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004; 10: 225-232.
• 26 Zangari M, Berno T, Zhan F. et al. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost 2012; 38: 768-779.
• 27 Dimopoulos M, Spencer A, Attal M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
• 28 Weber DM, Chen C, Niesvizky R. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
• 29 Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354: 2079-2080.
• 30 Galli M, Elice F, Crippa C. et al. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004; 89: 1141-1142.
• 31 Johnson DC, Corthals S, Ramos C. et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 2008; 112: 4924-4934.
• 32 Wu S, Yeh YM, Chen YP. et al. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. Ann Hematol 2012; 91: 1773-1778.